İntravitreal Triamsinolonun Kullanım Alanları

Yıl 2007, Cilt: 4 Sayı: 3, 98 - 107, 01.12.2007

Yusuf Özdemir

Öz

Triamsinolon asetonid, triamsinolonun uzun etkili depo preparatıdır. Triamsinolon, anlamlı minerokortikoid aktivite olmaksızın yüksek seçici glukokortikoid aktiviteye sahiptir. Triamsinolon asetonidin intravitreal olarak retinal damar hastalıklarına bağlı makula ödemi, proliferatif vitroretinopati, yaşa bağlı koroid neovaskularizasyonlu yaşa bağlı makula dejenerasyonu, inatçı pseudofak kistoid makula ödemi, kronik üveit, kronik kistoid makula ödemi, yırtıklı-delikli retina dekolmanlı hastalarda vitrektomi sırasında vitreusun tesbiti gibi farklı vitroretinal alanlarda kullanımı gittikçe artmaktadır

Anahtar Kelimeler

İntravitreal triamsinolon asetonid, glokom, retina damar hastalıkları, diabetik makula ödemi, kistoid makula ödemi

The Use of Intravitreal Triamcinolone in Ophthalmology

Öz

Triamcinolone acetonide is a long acting depot preperation of triamcinolone. Triamcinolone has highly selective glucocorticoid activity without significant mineralcortcoid action. Triamcinolone acetonide has increasingly been used for intravitreal injection in the treatment of various vitreoretinal diseases such as macular edema secondary to retinal vascular diseases, proliferative vitreoretinopathy, choroidal neovascularization form agerelated macular degeneration, diffuse diabetic macular edema, persistent psedophakic cystoid macular edema, chronic uveitis, chronic cystoid macular edema, identification of vitreous during vicrectomy in patients with rhegmatogenous retinal detachment

Anahtar Kelimeler

Intravitreal triamcinolone acetodine, glaucoma, retinal vascular diseases, diabetic macular edema, cystoid macular edema

Kaynakça

• Bressler NM, Bressler SB, Fine SL . Age- related Ophthalmol, 1988; 32: 75–413.
• Mitchell P, Smith W, Attebo K, et al. Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study. Ophthalmology,1995; 102: 1450–1460.
• Challa JK, Gillies MC, Penfold PL, et al. Exudative intravitreal triamcinolone: 18 month follow up. Aust NZJ Ophthalmol, 1998; 26: 277– 281.
• Penfold PL, Gyory JF, Hunyor AB, et al. Exudative intravitreal triamcinolone. A pilot study. Aust. NZ. J. Ophthalmol, 1995;23: 293–298. 5-Jonas JB
• Akkoyun I, Budde WM, et al. Intravitreal re-injection oftriamcinolone for exudative agerelated macular degeneration. Arch. Ophthalmol, 2004; 122: 218–222.
• Haddad WM, Souied E, Coscas G. Treatmentof exudative AMD with chorioretinal anastomosis
• photodynamic therapy with and without intravitreal injection of triamcinolone acetonide. ARVO-Abstracts, 2004; 3163/B: 798-799
• Bresnick GH. Diabetic retinopathy: a critical review highlighting diffuse macular edema. Ophthalmology, 1983; 90: 1301–1317.
• Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Ophthalmology, 1991; 98: 1594–1602.
• Degenring RF, Jonas JB. Serum levels of triamcinolone injection. Am. J. Ophthalmol, 2004; 137: 1142– 1143.
• Yıldırım Y, Ayata A, Ünal M. The effect of intravitreal triamcinolone acetonide on chronic diffuse diabetic macular edema resistant to conventional treatment. Retina Vitreus, 2005; 13,4:261-266
• Karacorlu M, Ozdemir H, Karacorlu S, et al. Regression neovascularization in proliferative diabetic retinopathy after intravitreal triamcinolone. Regression neovascularization triamcinolone. Int. Ophthalmol, 2004; 25: 113– 116.
• Al-Haddad CE, Jurdi FA, Bashshur ZF. Intravitreal triamcinolone acetonide for the management of diabetic papillopathy. Am. J. Ophthalmol,2004; 137: 1151–1153.
• Chen SD, Lochhead J, Patel CK, et al. Intravitreal ischaemic macular oedema caused by branch retinal vein occlusion. Br. J. Ophthalmol, 2004; 88: 154–155.
• Karaçorlu SA, Karaçorlu M, Özdemir H. The evaluation of macular changes after intravitreal triamcinolone acetonide in branch retinal vein occlusion. Retina Vitreus, 2005; 13,4: 273-277
• Çekiç O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina, 2005; 25: 851-855
• Hayreh SS, Klugman MR, Podhajsky P, et al. Argon laser panretinal photocoagulation in ischemic pressure after intravitreal triamcinolone acetodine injection.Am. J. Ophthalmol, 1990;138: 286-287.
• Çekiç O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina, 2005; 25:846-850
• Williamson TH, O’Donnell A. İntravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusıon. Am. J. Ophthalmol, 2005; 139 (5):860-866
• Ip MS, Gottlieb JL, Kahana A, et al. Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Arch. Ophthalmol, 2004; 122: 1131–1136
• Jonas JB, Kreissig I, Degenring RF. Repeated triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration. Graef. Arch. Clin. Exp. Ophthalmol, 2002; 240: 873–874.
• Jonas JB, Söfker A, Degenring RF. Intravitreal triamcinolone acetonide as additional tool in pars plana vitrectomy for proliferate diabetic retinopathy. Eur. J Ophthalmol, 2003;13: 468–473.
• Karacorlu M., Mudun B., Ozdemir H, et al. Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behcet disease. Am. J. Ophthalmol, 2004; 138: 289–291.
• Pathengay A. Intravitreal triamcinolone in serpiginous Ophtalmol, 2005; 53: 77-79
• Ünal M, Ayata A, Yıldırım Y. İntravitreal triamcinolone asetonide for treatment of sympathetic ophthalmia. Retina Vitreus, 2005; 13,4:311-314
• Jonas JB. Intravitreal triamcinolone acetonide as treatment of chronic focal immunologic corneal graft reaction. Graef. Arch. Clin. Exp. Ophthalmol, 2003; 241: 779–780.
• Reinhard T, Sundmacher R. Adjunctive intracameral application of corticosteroids in patients with endothelial immune reactions after penetrating keratoplasty. A pilot study. Transplant International. I. Transplant Int, 2002; 15: 81–88.
• Jonas JB, Kamppeter B. İntravitreal triamcinolone acetodine for persisting cystoid macular edema after penetrating keratoplasty. Cornea, 2006; 25 (2): 240-241
• Jonas JB, Hayler JK, Söfker A, et al. Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J. Glaucoma, 2001; 10: 284–287
• Alldredge CD, Garretson BR. Intravitreal triamcinolone for the treatment of idiopathic juxtafoveal telangiectasis. Retina, 2003; 23: 113–116.
• Jonas JB, Harley JK, Panda-Jonas S. Intravitreal injection of crytalline cortisone as treatment of pre-phthisical ocular hypotony. Graef. Arch. Clin. Exp. Ophthalmol, 2001; 239: 464-465
• Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive vitreoretinopathy. Br. J. Ophthalmol, 2001; 84: 1064–1067.
• Enaida H, Hata Y, Ueno A, et al. Possible benefits of triamcinolone-assisted pars plana vitrectomy for retinal diseases. Retina, 2003; 23: 764–770.
• Jonas JB, Sofker A, Degenring RF. İntravitreal triamcinolone acetonide as additional tool in pars plana vitrectomy for proliferate diabetic retinopathy. Eur. J. Ophthalmol, 2003; 13: 468-473.
• MunirWM, Pulido JS, Sharma MC. İntravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Canadian Journal of Ophthalmology, 2005; 40 (5): 598- 604 35-Kimura
• Triamcinolone acetonide assisted peeling of the internal limiting membrane. Am. J. Ophthalmol, 2004; 137: 172–173.
• Yamamoto N, Ozaki N, Murakami K. Triamcinolone acetonide facilitates removal of the epiretinal membrane and separation of the residual vitreous cortex in highly myopic eyes with retinal detachment due to a macular hole. Ophthalmologica, 2004; 218: 248–256.
• Jonas JB, Kreissig I, Budde WM. Cataract surgery combined with intravitreal injection of triamcinolone acetonide. Eur. J. Ophthalmol, 2005; 15(3): 329-353
• Habib MS, Cannon PS, Steel DHW. The combination of intravitreal triamcinolone and phacoemulsification surgery in patients with diabetic foveal edema and cataract. B.M.C Ophthalmol, 2005; 5: 15-21
• Yamakiri K, Uchino E, Kimura K, et al. Intracameral triamcinolone helps to visualize and remove the vitreous body in anterior chamber in cataract surgery. Am. J. Ophthalmol, 2004; 138: 650–652.
• Jonas JB, Kreissig I, Degenring RF. Cataract surgery after intravitreal injection oftriamcinolone acetonide. Eye, 2004; 18: 361–364. 41-Jonas
• triamcinolone acetonide for cataract surgery with iris neovascularisation. J. Cataract. Refract. Surg, 2002; 28: 2040–2041.
• Jonas JB, Degenring RF, Kreissig I, et al. Intraocular intravitreal triamcinolone acetonide injection. Ophthalmology, 2005; 112: 593-598
• Civerchia LL, Balent A. Treatment of pseudophakic cystoid macular edema by elevation of intraocular pressure. Ann. Ophthalmol, 1984; 16: 890–894.
• Becker B, Bresnick G, Chevrette L, et al. Intraocular pressure and its response to topical corticosteroids in diabetes. Arch. Ophthalmol, 1966; 76: 477–483.
• Jonas JB, Harder B, Kamppeter B. Inter- eye difference in diabetic macular edema after unilateral intravitreal injection of triamcinolone acetonide. Am. J. Ophthalmol, 2004; 138(6): 970-977
• Jonas J, Kreissıg I, Degenrıng R. Complication of infectious and sterile endophthalmitis triamcinolone acetonide. Br. J. Ophthalmol, 2004; 88: 92-95
• Nelson ML, Tennant MT, Sivalingam A, et al. Infectious and presumed noninfectious endophthalmitis triamcinolone acetonide injection. Retina, 2003; 23: 686–691.
• Rodney SB, Edward H. Effect of intravitreal triamcinolone acetodine on suspectibility into experimental bacterial endophthalmitis and subsequent respondse to treatment. Arch Ophthalol, 2005; 123: 649- 653
• Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment exudative and neovascular disease. Progress in Retinal and Eye Research, 2005; 24: 587- 611
• Çekiç O, Chang S, Tseng JJ, et al.Cataract progression after intravitreal triamcinolone injection. Am. J. Ophthalmol, 2005; 139:993-998 A.
• Intravitreal pressure elevation after after intravitreal after intravitreal of intraocular proliferative, 51-Chen SD
• Lochhead J, McDonald B., et al. Pseudohypopyon after intravitreal triamcinolone injection for the treatment of pseudophakic cystoid macular oedema. Br. J. Ophthalmol, 2004; 88: 843–844. 52-Sutter
• triamcinolone for radiation-induced macular edema. Arch. Ophthalmol, 2003; 121: 1491– 1493.
• Jaissle GB, Szurman P, Bartz-Schmidt KU. Nebenwirkungen und Komplikationen der intravitrealen Triamcinolonacetonid- Therapie. Ophthalmologe, 2004; 101: 121–128.
• Young S, Larkin G, Branley M, et al. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin. Exp. Ophthalmol, 2001; 29: 2–6.
• Degenring RF, Jonas JB. Rinsing ofthe cannula prior to intravitreal injection. Arch. Ophthalmol, 2004; 122: 1571–1572 .
• Yeung CK, Chan KP, Chan CK, et al. Cytotoxicity oftriamcinolon e on cultured human retinal pigment epithelial cells: comparison with dexamethasone and hydrocortisone. Jpn. J. Ophthalmol, 2004; 48: 236–242. Dr.